A review on hematologic malignant patients infected with 2019 novel coronavirus

Abstract

Since late 2019, when novel coronavirus pneumonia emerged in China and spread worldwide, there has been a need for data con-cerning the clinical characteristics of infected immunocompromised patients. It has been reported that a significant mortality rate occurs in individuals with underlying comorbidities such as hematologic malignancies. Therefore, it is vital to illustrate the clinical manifestations and outcomes of COVID-19 in these vulnerable patients and identify safe therapeutic strategies. This study reviewed the clinical course, laboratory findings, and risk factors associated with hematologic malignant patients with COVID-19 along with the management and therapeutic regimens.